Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience

Tsimberidou, Apostolia M.; Giles, Frank; Khouri, Issa F.; Bueso‐Ramos, Carlos E.; Pilat, Susan; Thomas, Deborah A.; Cortes, Jorge; Kurzrock, Razelle

doi:10.1093/annonc/mdi007

Cited by 50 publications

(32 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, 1 patient in the second study had a transient ischemic attack after completing treatment, and 1 patient developed atrial fibrillation/supraventricular tachycardia. 82,83 Other cardiovascular events, such as arrhythmias and pulmonary edema, also have been observed. 84 Oprelvekin also has been associated with allergic and hypersensitivity reactions, including anaphylaxis, and serious fluid retention, which has been fatal in some patients.…”

Section: Pharmacologic Treatmentmentioning

confidence: 99%

“…82 It is approved by the FDA for the prevention of severe thrombocytopenia after myelosuppressive chemotherapy in patients with nonmyeloid malignancies who are at high risk for this toxicity. 82 Two small, single-arm studies have explored its use in patients with bone marrow failure, including those with bone marrow failure caused by MDS. 82,83 In the pilot study, median platelet counts at baseline were 12 3 10 9 /L, and 38% of patients showed a platelet response.…”

Section: Pharmacologic Treatmentmentioning

confidence: 99%

“…82 Two small, single-arm studies have explored its use in patients with bone marrow failure, including those with bone marrow failure caused by MDS. 82,83 In the pilot study, median platelet counts at baseline were 12 3 10 9 /L, and 38% of patients showed a platelet response. 83 Of the 6 responders in that study, 1 patient had RA, 1 patient had RA with ringed sideroblasts (RARS), and 3 patients had RAEB; the other responder had aplastic anemia.…”

Section: Pharmacologic Treatmentmentioning

confidence: 99%

“…83 In the second study, median platelet counts were 17 3 10 9 /L at baseline, and 27% of patients responded to treatment with either a major or minor platelet response (6 patients) or a multilineage response (3 patients). 82 Of the responders, 4 patients had RAEB, 1 patient had RARS, and the remaining patients had chronic myelomonocytic leukemia or aplastic anemia. The duration of response ranged from 1.4 months to !34.5 months.…”

Section: Pharmacologic Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

Kantarjian

Giles

List

et al. 2007

Cancer

215

179

View full text Add to dashboard Cite

Thrombocytopenia and platelet dysfunction contribute to hemorrhagic complications in the myelodysplastic syndromes (MDS). Reliable data regarding the frequency and consequences of thrombocytopenia in MDS are lacking. An extensive literature review indicated that the prevalence of thrombocytopenia (platelets <100 3 10 9 /L) in MDS ranged from 40% to 65%; the median frequency of thrombocytopenia prior to any MDS therapy was 65% (range, 23-93% high-risk disease. Treatment-related thrombocytopenia was observed in studies that involved azacitidine, tipifarnib, decitabine, lenalidomide, sirolimus, and combination chemotherapy with idarubicin, cytarabine, and topotecan. The reported incidence of hemorrhagic complications in the literature ranged from 3% to 53%, and the frequency of hemorrhagic deaths ranged from 14% to 24%.At MDACC, 460 patients had a coded cause of death: hemorrhage as a contributory cause of death, 20%; hemorrhage as the only cause of death, 10%. Thrombocytopenia was common in MDS, and there was an increased prevalence in higher risk IPSS categories. Many approved and investigational MDS therapies caused or exacerbated preexisting thrombocytopenia. The incidence of severe bleeding in MDS was greater than reported in current guidelines. Cancer

show abstract

Section: Pharmacologic Treatmentmentioning

confidence: 99%

Section: Pharmacologic Treatmentmentioning

confidence: 99%

Section: Pharmacologic Treatmentmentioning

confidence: 99%

Section: Pharmacologic Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

Kantarjian

Giles

List

et al. 2007

Cancer

215

179

View full text Add to dashboard Cite

show abstract

“…thrombopoietin mimetics) are being investigated as alternatives to platelet transfusions (5,6). Based on the duration and severity of thrombocytopenia, neonates with sepsis and/or NEC could be potential candidates for therapy with thrombopoietic growth factors.…”

mentioning

confidence: 99%

Effects of Sepsis on Neonatal Thrombopoiesis

et al. 2008

View full text Add to dashboard Cite

ABSTRACT:We serially evaluated the effects of sepsis and/or necrotizing enterocolitis (NEC) on neonatal thrombopoiesis, using a panel of tests that included platelet counts, thrombopoietin concentrations (Tpo), circulating megakaryocyte progenitor concentrations (CMPs), and reticulated platelets (RPs). Variables analyzed included sepsis type, time after onset of sepsis, platelet counts, and gestational (GA) and postconceptional ages (PCA). Twenty neonates were enrolled. Ten had Gram-negative, six had Gram-positive, and four had presumed sepsis. Four neonates had NEC stage II or higher, and six developed thrombocytopenia. Overall, septic neonates had significantly elevated Tpo concentrations and circulating megakaryocyte progenitors. The highest Tpo levels were associated with Gramnegative or presumed sepsis. RP percentages were increased only in neonates with low platelet counts, while RP counts (RP% ϫ platelet count) were elevated in neonates with high platelet counts. Our findings suggest that septic neonates up-regulate Tpo production, leading to increased megakaryocytopoiesis and platelet release, although the degree of upregulation is moderate. The changes in RP% and RP count most likely reflect increased thrombopoiesis with variable degrees of platelet consumption. In addition, our findings suggest that different factors, likely including level of illness and/or specific platelet or bacterial products, can down-regulate the magnitude of the thrombopoietic response.

show abstract

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review

Desborough

Estcourt

Chaimani

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the relative efficacy of different treatments for thrombocytopenia (artificial platelet substitutes, platelet-poor plasma, fibrinogen, rFVIIa, rFXIII, thrombopoietin mimetics, antifibrinolytic drugs or platelet transfusions) in patients with chronic bone marrow failure and to derive a hierarchy of potential alternate treatments to platelet transfusions.

show abstract

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience

Abstract: Low-dose IL-11 has activity in patients with BMF and is generally well tolerated.

Cited by 50 publications

References 28 publications

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

Effects of Sepsis on Neonatal Thrombopoiesis

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review

Contact Info

Product

Resources

About